Search results
Why Alnylam Pharmaceuticals Topped the Market Today
Motley Fool· 10 months agoWhat happened The fight against Alzheimer's disease seems to be advancing, and one biotech developing a treatment for the degenerative brain disorder...
Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today
Motley Fool· 2 years agoShares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market...
Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Simply Wall St. via Yahoo Finance· 12 months agoAlnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) price-to-sales (or "P/S") ratio of 20.1x might make it...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 weeks agoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript May 2, 2024 Alnylam...
Intellia, Other CRISPR Stocks Hammered On Safety Concerns In New Gene-Editing Test
Investor's Business Daily· 2 years agoIntellia Therapeutics said early Friday it found a way to knock out the gene responsible for a rare...
Pfizer Posted a Steep Loss. Is It Time to Sell?
Motley Fool· 7 months agoIt's been about a couple of weeks since Pfizer (NYSE: PFE) promised to make Halloween extra spooky by warning us that third-quarter results would be...
Why Shares of Vir Biotechnology Are Plunging Thursday
Motley Fool· 10 months agoShares of Vir Biotechnology (NASDAQ: VIR) were down more than 44% as of 10:45 a.m. on Thursday after...
Why Shares of BridgeBio Pharma Skyrocketed This Week
Motley Fool· 10 months agoShares of BridgeBio Pharma (NASDAQ: BBIO) were up 90% for the week as of 10:25 a.m. ET on Friday, according to data provided by S&P Global Market...
Why BridgeBio Pharma Stock Is Plunging Today
Motley Fool· 11 months agoShares of the small-cap biotech BridgeBio Pharma (NASDAQ: BBIO) were down by 7.2% on moderate volume as of 1:09 p.m. ET Thursday. The big loss came after...
Newly optimistic, biotech investors weigh lessons of sector’s downturn
BioPharma Dive via Yahoo Finance· 4 months agoInvestors and executives interviewed by BioPharma Dive at J.P. Morgan say new companies have to be...
